Core Viewpoint - Maravai LifeSciences has faced significant stock price declines due to concerns over its financial reporting and internal controls, leading to a class action lawsuit from investors [1][2][4]. Financial Reporting Issues - On March 18, 2025, Maravai warned investors against relying on its Q2 and Q3 2024 financial reports, stating they would be restated due to improper revenue recognition [3][6]. - The company acknowledged that its disclosure controls and procedures were ineffective, which contributed to the inaccuracies in financial reporting [3][6]. Stock Price Impact - Following the announcement on March 19, 2025, Maravai's shares fell nearly 6%, compounding a previous drop of 21% on February 25, 2025, when the company postponed its Q4 and FY 2024 earnings release [1][5]. - An analyst from Baird downgraded Maravai's rating from outperform to neutral and reduced the price target from $9 to $3 after the February announcement [5]. Class Action Lawsuit - A class action lawsuit has been filed against Maravai, representing investors who purchased securities between August 7, 2024, and February 24, 2025, alleging false and misleading statements regarding financial statements and internal controls [2][4]. - The lawsuit claims that Maravai failed to disclose crucial information about its financial reporting practices, which led to investor losses [4][5]. Revenue Recognition Concerns - Maravai is under scrutiny for potentially recording unearned revenues and overstating goodwill, with specific instances of revenue being inaccurately recognized by approximately $3.9 million in Q2 2024 [5][6]. - The company is currently assessing the adequacy of its internal controls over financial reporting, particularly concerning revenue recognition [6].

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action securities lawsuit due to alleged securities fraud impacting investors between August 7, 2024, and February 24, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the Company's business and prospects [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased Maravai securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=138831&fr ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai LifeSciences To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW Y ...

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1] Allegations Against Defendants - The complaint alleges that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is claimed that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The lawsuit states that Maravai's goodwill was overstated [2] - As a result of these issues, the positive statements made by the Defendants about the company's business and prospects were materially misleading [2] Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3] - The lead plaintiff selects counsel to represent the class, and their ability to recover is not affected by the decision to serve as a lead plaintiff [3] Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm aims to protect investors and consumers from fraud and negligence by businesses [4]

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Maravai ...

Lead Plaintiff Deadline is May 5, 2025CLICK HERE TO PROVIDE CONTACT INFORMATION AND JOIN THE CASENEW YORK, March 25, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ:MRVI) on behalf of all persons and entities that purchased or otherwise acquired Maravai securities between August 7, 2024 and February 24, 2025, both dates inclusive ...

Core Viewpoint - A class action securities lawsuit has been filed against Maravai LifeSciences Holdings, Inc. due to alleged securities fraud affecting investors between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the Company's business and prospects [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2024 Earnings Conference Call March 20, 2025 5:00 PM ET Company Participants Deb Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Conference Call Participants Matt Stanton - Jeffries Doug Schenkel - Wolfe Research Matt Larew - William Blair Ricki Levitus - Guggenheim Tejas Savant - Morgan Stanley Dan Arias - Stifel Catherine Schulte - Baird Matt Sykes - Goldman Sachs Brandon Coulliard - Wells Fargo Anna Snopkowski - KeyBanc Capital Markets Oper ...